Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Return on Equity (2016 - 2025)

Celldex Therapeutics has reported Return on Equity over the past 15 years, most recently at 0.46% for Q4 2025.

  • Quarterly results put Return on Equity at 0.46% for Q4 2025, down 25.0% from a year ago — trailing twelve months through Dec 2025 was 0.46% (down 25.0% YoY), and the annual figure for FY2025 was 0.41%, down 14.0%.
  • Return on Equity for Q4 2025 was 0.46% at Celldex Therapeutics, down from 0.36% in the prior quarter.
  • Over the last five years, Return on Equity for CLDX hit a ceiling of 0.16% in Q4 2021 and a floor of 0.48% in Q3 2023.
  • Median Return on Equity over the past 5 years was 0.3% (2025), compared with a mean of 0.3%.
  • Biggest five-year swings in Return on Equity: rose 28bps in 2024 and later fell -25bps in 2025.
  • Celldex Therapeutics' Return on Equity stood at 0.16% in 2021, then plummeted by -103bps to 0.33% in 2022, then fell by -25bps to 0.42% in 2023, then soared by 51bps to 0.21% in 2024, then crashed by -123bps to 0.46% in 2025.
  • The last three reported values for Return on Equity were 0.46% (Q4 2025), 0.36% (Q3 2025), and 0.29% (Q2 2025) per Business Quant data.